Abstract 4399
Background
Data on the efficacy and safety of all targeted therapies for metastatic renal cell carcinoma (mRCC) including sunitinib are collected in the Czech RENIS patient registry. RENIS thus provides a uniquely large sample of long-term effectiveness and prognostic data of sunitinib according to adverse/risk factors measured by the Memorial Sloan Kettering Cancer Center (MSKCC) score. The aim of this study was to analyze the long-term overall (OS) and progression-free survival (PFS) of sunitinib, when used as 1st line treatment, based on MSKCC risk group scores including MSKCC scores for two intermediate subgroups.
Methods
Data from mRCC patients treated using sunitinib in the 1st line were collected in RENIS between 06/2007 and 02/2018. OS/PFS were then stratified based on MSKCC scores: a) favorable risk (0 adverse factors (AF)), b) intermediate risk (pooled 1–2 AFs), and c) poor risk (3+ AFs). The OS/PFS of the intermediate risk group was further stratified into two subgroups: i) 1 AF and ii) 2 AFs. All OS/PFS data were analyzed using Kaplan-Meier estimates. Differences in OS/PFS between risk groups were assessed using median survival, 95% confidence intervals (CI), and the log-rank test. Then we assessed the OS/PFS for 1-, 3-, and 5-year survival.
Results
Over the 11-year follow-up, 2390 patients were treated using sunitinib with 806, 1450, and 134 patients in the favorable, intermediate, and poor MSKCC risk groups. The more favorable MSKCC risk group was accompanied by an improved OS and PFS (p < 0.001). Regarding the MSKCC for the two intermediate sub-groups, 1 AF was associated with improved survival compared to 2 AFs (p < 0.001) (Table).Table:
957P OS and PFS results for sunitinib treatment based on MSKCC risk groups
MSKCC favorable | MSKCC intermediate | MSKCC poor | MSKCC intermediate | All patients | ||
---|---|---|---|---|---|---|
1 AF | 2 AFs | |||||
Overall survival | ||||||
Median survival (95% CI) | 44.7months (40.9-50.5) | 24.1months (21.9-26.0) | 9.5months (7.2-14.1) | 28.2months (25.9-30.7) | 16.2months (14.5-20.2) | 28.5months (26.3-30.5) |
1-year survival (95% CI) | 85.0% (82.4-87.6) | 69.1% (66.6-71.7) | 44.3% (35.0-53.7) | 74.3% (71.4-77.2) | 58.0% (53.1-62.9) | 73.3% (71.4-75.2) |
3-year survival (95 %CI) | 57.3% (53.4-61.3) | 37.1% (34.1-40.1) | 9.6% (3.1-16.2) | 42.0% (38.3-45.7) | 26.3% (21.4-31.2) | 42.9% (40.5-45.2) |
5-year survival (95% CI) | 35.6% (31.2-40.1) | 23.4% (20.4-26.4) | 3.2% (0.0-8.8) | 26.5% (22.7-30.3) | 16.5% (11.8-21.2) | 26.8% (24.3-29.2) |
n | 806 | 1450 | 134 | 969 | 481 | 2390 |
Log-rank p-value | < 0.001 | < 0.001 | - | |||
Progression-free survival | ||||||
Median survival (95% CI) | 17.0months (15.4-18.8) | 9.0months (8.3-9.5) | 4.5months (3.9-6.1) | 10.1months (9.4-11.4) | 6.2months (5.5-7.5) | 10.6months (9.9-11.5) |
1-year survival (95% CI) | 61.8% (58.3-65.3) | 40.7% (38.0-43.4) | 20.8% (13.1-28.5) | 45.1% (41.8-48.4) | 31.6% (27.1-36.1) | 46.9% (44.7-49.0) |
3-year survival (95 %CI) | 25.1% (21.7-28.5) | 13.0% (11.0-15.1) | 1.8% (0.0-5.1) | 15.9% (13.2-18.6) | 7.0% (4.2-9.7) | 16.6% (14.9-18.4) |
5-year survival (95% CI) | 10.4% (7.7-13.2) | 8.0% (6.2-9.8) | 1.8% (0.0-5.1) | 9.7 (7.3-12.0) | 4.5% (2.1-6.9) | 8.4% (7.0-9.9) |
n | 806 | 1450 | 134 | 969 | 481 | 2390 |
Log-rank p-value | < 0.001 | < 0.001 | - |
Conclusions
Better MSKCC risk scores were associated with significantly longer OS and PFS. To our knowledge, this is the largest published sunitinib mRCC cohort described relative to MSKCC risk groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Finek: Honoraria (self): Amgen; Honoraria (self): BMS; Honoraria (self): Roche; Honoraria (self): Bayer; Honoraria (self): Teva; Honoraria (self): MSD; Honoraria (self): Merck; Honoraria (self): Sanofi; Honoraria (self): Pierre Fabre. A. Poprach: Honoraria (self): Pfizer; Honoraria (self): Roche; Honoraria (self): Ipsen; Honoraria (self): Novartis; Honoraria (self): BMS; Honoraria (self): Bayer. B. Melichar: Honoraria (self): BMS; Honoraria (self): Merck; Honoraria (self): MSD; Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): Astellas Pharma; Honoraria (self): Pfizer; Honoraria (self): Bayer. J. Kopecky: Honoraria (self): BMS; Honoraria (self): Novartis; Honoraria (self): Pfizer. M. Zemanova: Advisory / Consultancy: Novartis; Honoraria (self): Eli Lilly; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Boehringer Ingelheim. T. Buchler: Honoraria (self): Amgen; Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: BMS; Advisory / Consultancy: Pfizer; Travel / Accommodation / Expenses: Janssen. K. Kopeckova: Honoraria (self): Novartis; Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: Pfizer. T. Mlcoch: Full / Part-time employment: Value Outcomes. T. Dolezal: Full / Part-time employment: Value Outcomes. All other authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract